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Abstract: The structural isomer of asymmetric dimethylarginine (ADMA), symmetric 
dimethylarginine (SDMA), is eliminated almost entirely by urinary excretion and 
considered a sensitive index of glomerular filtration rate (GFR). However, reports on this 
relationship in healthy subjects younger than 18 years of age are rare. Therefore, our aim 
was to investigate relations between endogenous dimethylarginines and renal function 
indices in healthy children and adolescents. We studied 40 subjects aged 3–18 years free of 
coexistent diseases or subclinical carotid atherosclerosis. A serum creatinine-derived 
estimated GFR (eGFR) was calculated by the revised bedside Schwartz equation.  
L-arginine, ADMA and SDMA were measured by liquid chromatography-tandem mass 
spectrometry. Mean eGFR was 122 ± 22 (SD) mL/min per 1.73 m2. Creatinine and eGFR 
exhibited closer correlations with the SDMA/ADMA ratio (r = 0.64, p < 0.0001; r = −0.63, 
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p < 0.0001, respectively) than with SDMA (r = 0.31, p = 0.05; r = −0.35, p = 0.03). Neither 
creatinine nor eGFR correlated with ADMA or L-arginine. Adjustment for age or height 
only slightly attenuated the associations between the SDMA/ADMA ratio and eGFR or 
creatinine. Our findings suggest the superiority of the SDMA/ADMA ratio over SDMA as 
a renal function index in healthy children. Thus, further studies are warranted to verify our 
preliminary results in a larger group of subjects below 18 years of age. 




Symmetric dimethylarginine (SDMA), eliminated almost entirely by urinary excretion, is 
considered an index of glomerular filtration rate (GFR) and is even referred to as an  
“expensive creatinine” [1]. Irrespective of the still debated pathogenic role of SDMA in patients with 
renal diseases [2], SDMA appears a more sensitive marker of mild GFR depression than its structural 
isomer asymmetric dimethylarginine (ADMA), and SDMA levels rise linearly with decreasing GFR at 
a normal GFR and in mild-to-moderate renal insufficiency [3,4]. According to a meta-analysis [5], 
SDMA was a good predictor of renal function with an average correlation coefficient (r) of 0.77 
between a reciprocal of SDMA and various estimates of GFR with even higher r-values (0.85) for 
inulin clearance, the golden standard for measurement of GFR, whereas the respective measures were 
markedly lower for ADMA.  
However, out of 17 full-text source publications underlying this meta-analysis, only one dealt with 
subjects below 18 years of age [6]. Additionally, that report and the majority of later studies relating 
renal function to dimethylated L-arginine analogs in children mainly focused on chronic kidney disease 
(CKD) [6–8] or type 1 diabetes [9–11].  
Therefore, our aim was to investigate relations between endogenous dimethylarginines and indices 
of renal function in healthy children and adolescents.  
2. Results 
Characteristics of the study subjects and plasma levels of L-arginine, ADMA and SDMA are shown 
in Tables 1 and 2. None of the participants exhibited the presence of carotid plaques or focal  
intimal thickening. 
ADMA and SDMA were mutually interrelated (r = 0.61, p < 0.0001). SDMA and estimated GFR 
(eGFR) correlated with homocysteine (r = 0.42, p = 0.007 and r = −0.57, p = 0.0001, respectively), 
and a weak tendency towards a negative relationship between ADMA and age was observed  
(r = −0.22, p = 0.17). Averaged intima-media thickness (IMT) of the common carotid artery was 
unrelated to ADMA, SDMA and eGFR (p > 0.25).  
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Table 1. Clinical and biochemical characteristics of 40 study subjects. 
Characteristic  
Age (years)  
Male gender (M/F) 
10.1 ± 3.6  
33/7 
Parental history of premature coronary artery disease 10 (25%) 
Height (percentiles) 48 ± 28 
Weight (percentiles) 43 ± 24  
Waist circumference (cm) 63 (56–74) 
Creatinine (µmol/L) 40.2 (36.2–49.0) 
Estimated glomerular filtration rate (mL/min per 1.73 m2) 122.4 (109.7–136.1) 
Low-density lipoproteins-cholesterol (mmol/L) 2.2 (1.8–2.7) 
High-density lipoproteins-cholesterol (mmol/L) 1.5 (1.3–1.8) 
Triglycerides (mmol/L)  0.72 (0.54–0.94) 
Glucose (mmol/L) 4.6 (4.4–5.1) 
Homocysteine (µmol/L) 8.5 (7.4–10.1) 
Averaged intima-media thickness of the common carotid artery (mm) 0.45 (0.41–0.53) 
Data are shown as means ± SD, medians (interquartile range) or n (%). 
Table 2. Plasma levels of L-arginine, asymmetric dimethylarginine (ADMA) and  
symmetric dimethylarginine (SDMA). 
Metabolite Mean ± SD 
L-arginine (µmol/L) 69 ± 22 
ADMA (µmol/L) 0.63 ± 0.12 
SDMA (μmol/L) 0.56 ± 0.10 
SDMA/ADMA ratio 0.91 ± 0.16 
ADMA: asymmetric dimethylarginine; SDMA: symmetric dimethylarginine. 
Creatinine and eGFR exhibited stronger correlations with the SDMA to ADMA ratio (Table 3; 
Figure 1a, Figure 2a) than with SDMA (Table 3; Figure 1b, Figure 2b). These differences were even 
more pronounced after exclusion of two subjects with serum creatinine <26 µmol/L or an  
eGFR >160 mL/min per 1.73 m2 (SDMA/ADMA vs. ln (creatinine): r = 0.62, p < 0.0001; SDMA vs. 
ln (creatinine): r = 0.22, p = 0.18; SDMA/ADMA vs. eGFR: r = –0.63, p < 0.0001; SDMA vs. eGFR:  
r = −0.28, p = 0.09). Neither creatinine nor eGFR correlated significantly with ADMA or L-arginine  
(p ≥ 0.17) (Table 3). 
Table 3. Pearson’s correlation coefficients between renal indices and ADMA, SDMA  
and L-arginine. 
 eGFR Ln (creatinine) 
ADMA 0.19 −0.22 
SDMA −0.35 ** 0.31 * 
SDMA/ADMA ratio −0.63 *** 0.64 *** 
L-arginine 0.02 −0.01 
* p = 0.05, ** p = 0.03, *** p < 0.0001. ADMA: asymmetric dimethylarginine; eGFR: estimated glomerular 
filtration rate; SDMA: symmetric dimethylarginine. 
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Figure 1. A closer positive correlation of ln-transformed serum creatinine with the 
SDMA/ADMA ratio (a) than with plasma SDMA (b).  
  
Figure 2. A closer inverse correlation of estimated glomerular filtration rate (eGFR) with 
the SDMA/ADMA ratio (a) than with plasma SDMA (b). 
 
The associations between the indices of renal function and SDMA or the SDMA/ADMA ratio were 
only slightly attenuated upon adjustment for age or height (Table 4). The observed relations were not 
substantially changed on exclusion of two subjects with an elevated level of C-reactive protein (CRP)  
(>5 mg/L) and after limitation of the analysis either to 33 boys or to 30 subjects with a negative 
parental history of premature coronary artery disease. 
Table 4. Effects of adjustment for age and height on the relations between indices of renal 
function and endogenous dimethylarginines. 
Relationship Mean standardized regression coefficient (β) ± SEM (p-values in parentheses) 
Unadjusted Age-adjusted Height-adjusted 
SDMA vs. eGFR −0.35 ± 0.15 (0.03) −0.36 ± 0.18 (0.06) −0.33 ± 0.18 (0.08) 
SDMA/ADMA vs. eGFR −0.63 ± 0.13 (<0.0001) −0.52 ± 0.15 (0.001) −0.52 ± 0.14 (0.0008) 
SDMA vs. ln (creatinine)  0.31 ± 0.15 (0.05) 0.52 ± 0.27 (0.06) 0.45 ± 0.28 (0.12) 
SDMA/ADMA vs. ln (creat.) 0.64 ± 0.12 (<0.0001) 0.75 ± 0.22 (0.001) 0.80 ± 0.22 (0.0009) 
ADMA: asymmetric dimethylarginine; creat.: creatinine; eGFR: estimated glomerular filtration rate; SDMA: symmetric 
dimethylarginine; SEM: standard error of the mean. 
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3. Discussion 
Our salient observation was a closer association of renal function indices with the SDMA/ADMA 
ratio than with SDMA in children and adolescents free of coexistent diseases or subclinical  
carotid atherosclerosis.  
3.1. Comparison with Other Studies Relating Renal Function to Endogenous Dimethylarginines  
in Children 
Plasma L-arginine, ADMA and SDMA levels in the study participants were similar to those 
previously reported for liquid or gas chromatography–tandem mass spectrometry in healthy  
children [7,12–14]. A positive correlation between SDMA and homocysteine might have been due to 
the dependence of both these parameters on renal function.  
Our findings are partially consistent with the report by Brooks et al. [7] who observed that 
creatinine-derived eGFR correlated with SDMA (r = −0.73), SDMA/ADMA ratio (r = −0.74) and only 
weakly with ADMA (r ≈ −0.33) in data pooled from 28 children and adolescents aged 13 ± 1 years 
with stage 2–3 CKD and 10 healthy age-matched siblings. Intriguingly, 15 years ago an early paper by 
Goonasekera et al. [6] described a closer correlation of ADMA (r = −0.77) than SDMA (r = −0.38) 
with eGFR derived from plasma creatinine by the Morris formula in 38 hypertensive children and 
adolescents aged 1–18 years (median, 8 years) with mainly nephrogenic hypertension and mildly 
depressed eGFR.  
We observed a weaker correlation between eGFR and SDMA (r = −0.35) than estimated according 
to a meta-analysis by Kielstein et al. [5] on the basis of 18 studies involving a total of 2136 subjects. 
Nevertheless, that meta-analysis focused mainly on adult subjects and our results are in keeping with 
data by Marcovecchio et al. [10] who reported a similar r-value (–0.38) between SDMA and plasma 
clearance of Inutest—branched chain polyfructosan with a Stokes radius profile equivalent to  
inulin—in 183 children aged 14.8 ± 4.1 years with type 1 diabetes and a mean eGFR of  
149 ± 32 mL/min per 1.73 m2 of body-surface area. Thus, the present study has extended the evidence 
supporting potential utility and limitations of an assay of endogenous dimethylarginines as an index of 
eGFR to healthy children. Nevertheless, our preliminary data require validation in a larger group  
of subjects. 
3.2. Proposed Mechanisms of the Close Relationship between Renal Function Indices and the SDMA 
to ADMA Ratio 
A close inverse correlation between eGFR and the SDMA/ADMA ratio might appear unexpected 
because an elevated ADMA/SDMA ratio had been previously suggested as a hallmark of depressed 
activity of cytosolic dimethylarginine dimethylaminohydrolases (DDAHs) [1,15], a family of cytosolic 
enzymes which hydrolyze over 80% of ADMA generated daily to L-citrulline and dimethylamine but 
are inactive towards SDMA [16–20]. However, this concept emerged from early reports on elevated 
ADMA in subjects with a given disease or risk factor with reference to matched healthy  
controls [15,21,22] usually exhibiting unchanged eGFR, the major determinant of SDMA levels. This 
preferential ADMA accumulation was putatively linked to depressed DDAH activity in experimental 
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models of the disease [18–20]. Nevertheless, our study subjects exhibited no evidence of abnormalities 
in which excessive ADMA accumulation or DDAH down-regulation had previously been  
shown [19,20,23]. Accordingly, it might be hypothesized that the effect of renal function on the  
inter-individual variability of the SDMA/ADMA ratio might have been more pronounced in this 
selected group of subjects. In addition, the calculation of the ratio could better reflect renal function 
because this approach probably accentuated the contribution of the renal ability to excrete SDMA 
(closely linked to GFR values) upon adjustment to the levels of ADMA, the vast majority of which is 
metabolized by DDAHs [17], i.e., independently of GFR.  
In the present study, eGFR and ADMA were unrelated, whereas SDMA and ADMA were 
positively and moderately correlated with each other. As pointed out by Kielstein et al. [5], both 
ADMA and SDMA are produced in every nucleated cell, being liberated during catabolism of proteins 
with dimethylated arginine residues. Although there are different profiles of methyl-accepting protein 
substrates for protein arginine methyltransferases type I and type II (catalyzing ADMA and SDMA 
formation, respectively) [24], it has long been recognized that cultured endothelial cells release both 
ADMA and—albeit less—also SDMA [25,26]. Therefore, generation of both free ADMA and SDMA 
is dependent on the activity of protein arginine methyltransferases and related to protein turnover  
rate [27], whereas SDMA concentrations are also influenced by renal function, which provides a 
rationale for the ability of the SDMA/ADMA ratio to distinguish a relatively “pure” effect of GFR.  
3.3. Study Limitations 
That we have based eGFR exclusively on serum creatinine, constitutes a major limitation of the 
present study, in addition to a small number of the study participants. Tutarel et al. [28] demonstrated 
that SDMA exhibited a markedly better correlation with cystatin C-based eGFR (by the Larsson 
formula) than eGFR calculated from serum creatinine by the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) or the Modification of Diet in Renal Disease (MDRD) study equations in  
97 young adults with congenital heart disease and a normal eGFR in almost all of the subjects. On the 
other hand, Marcovecchio et al. [10] reported a similar magnitude of moderate correlations of  
Inutest-derived GFR with SDMA and creatinine-derived eGFR in children with type 1 diabetes and 
normal or elevated eGFR due to hyperfiltration. A recent paper by Wasilewska et al. [8] suggested 
even better performance of SDMA than cystatin C for the detection of early CKD stages in children. 
However, in that report ADMA was not measured and SDMA was quantified by an enzyme-linked 
immunosorbent assay [8], considered less reliable than liquid chromatography-tandem mass 
spectrometry for detection of intergroup differences in dimethylarginines [29–31]. Therefore, future 
comparisons of SDMA and the SDMA/ADMA ratio with the reference to GFR measures based also on 
other markers than serum creatinine might provide further insight into a potential utility of these 
indices for renal function assessment in children and adolescents. 
Although exclusively healthy children were entered into the study, it cannot be excluded that some 
of them might have exhibited accelerated early atherogenesis, known to be associated with increased 
ADMA levels not only in adults [32] but also in pre-pubertal children [33], which could be a potential 
additional source of data variability. However, the absence of subclinical carotid atherosclerosis was 
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confirmed by ultrasound and averaged common carotid IMT remained within the previously reported 
normal range [34] in all the study participants.  
4. Experimental Section  
4.1. Study Subjects 
We studied 40 healthy children and adolescents (33 boys and seven girls) aged 3.4–17.9 years 
(median, 10.6 years). Exclusion criteria included congenital heart or pulmonary defects, clinical or 
biochemical evidence of renal or hepatic pathology, hypertension, diabetes, obesity, and any other 
significant chronic coexistent diseases, acute disorders or relevant abnormalities in routine blood or 
urine analyses. Additionally, those with ultrasound evidence of atherosclerotic plaques in carotid 
arteries were also excluded. 
4.2. Study Protocol 
The study was performed in accordance with the Helsinki Declaration, the protocol had been 
approved by the ethics committee of the Medical University of Silesia and written informed consent 
was obtained from the parents of each participant.  
Demographical data and medical history were recorded according to a pre-specified questionnaire and 
anthropometric measurements (height, weight, waist circumference) were performed. Additionally, 
ultrasonography of carotid arteries was performed to confirm the absence of atherosclerotic plaques.  
On a separate day in the morning, about 10 mL of blood was drawn from an antecubital vein after 
overnight fast into sampling tubes containing ethylenediaminetetraacetic acid or no anticoagulant, 
centrifuged and the collected portions of serum and plasma were frozen initially at −20 °C  
(and −70 °C in case of prolonged storage of samples) until assayed. 
Biochemical analyses included lipids, creatinine, glucose, homocysteine and CRP. Creatinine was 
measured by the Jaffe assay with the isotope dilution mass spectrometry (IDMS)-traceable calibration 
(Roche Hitachi Chemistry Analyzer, Roche Diagnostics, Basel, Switzerland). This method exhibited a 
percent bias (with 95% confidence intervals) of no more than 5% with the reference to IDMS for 
serum creatinine below 150 µmol/L [35]. CRP and homocysteine were quantified by immunoturbidometry 
(Roche Diagnostics) and a chemiluminescent microparticle immunoassay (Abbott Diagnostics, Abbott 
Park, IL, USA), respectively.  
Plasma concentrations of L-arginine, ADMA and SDMA were measured by means of liquid 
chromatography-electrospray tandem mass spectrometry methods with an isotope-labeled internal 
standard as described in detail elsewhere [36]. The imprecision of this method was 4.5%, 5.5% and 3.9% 
for L-arginine, ADMA and SDMA, respectively, with accuracies better than 5% for all the substances.  
An eGFR was calculated from serum creatinine and the height by the revised bedside Schwartz 
equation [37], which has been validated also for children and adolescents with normal renal  
function [38]. 
The common carotid artery, carotid bulb and internal carotid artery were visualized on both sides by 
B-mode imaging in the longitudinal plane using a high-resolution ultrasound device (iU22 xMATRIX 
Ultrasound System, Philips Healthcare, Best, The Netherlands) with a 12-MHz linear digital 
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ultrasound probe by an investigator (Jarosław Rycaj) who was unaware of characteristics of the 
subjects. The image was recorded and stored for off-line analysis by manual tracing to measure IMT. 
As proposed previously [39], plaques were defined as focal structures encroaching into the arterial 
lumen of at least 0.5 mm or 50% of the surrounding IMT value. IMT was measured at end-diastole on 
the far wall of the common carotid artery within a 1 cm segment immediately proximal to the carotid 
bulb and the final value was averaged from three measurements per each side [39]. 
4.3. Statistical Analysis 
Values are expressed as means ± SD (standard deviation) for continuous variables with normal 
distribution, medians (interquartile range) for not normally distributed continuous data, and  
numbers (%) for categorical variables. The accordance with a normal distribution was checked by the 
Lilliefors test. Bivariate correlations were estimated by Pearson’s correlation coefficients (r). In order 
to obtain a normal distribution, logarithmic transformation (ln, natural logarithm) was applied when 
necessary. To test an independent relationship between selected parameters, multiple regression was 
applied and mean standardized regression coefficients (β), their standard errors (SEM) and respective 
p-values for individual variables were shown. A p-value below 0.05 was inferred significant. All 
statistical tests were performed using STATISTICA (data analysis software system, version 10.0; 
StatSoft, Inc., Tulsa, Oklahoma, USA, 2011). 
5. Conclusions  
Our findings suggest the superiority of the SDMA/ADMA ratio over SDMA as an index of renal 
function in healthy children and adolescents. Nevertheless, further studies are warranted to verify these 
preliminary results in a large cohort of subjects below 18 years of age. 
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